<DOC>
	<DOCNO>NCT00003127</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient metastatic , recurrent , refractory endometrial cancer .</brief_summary>
	<brief_title>S9720 Combination Chemotherapy Treating Patients With Metastatic , Recurrent , Refractory Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy paclitaxel carboplatin amifostine progression free survival overall survival patient metastatic recurrent epithelial endometrial carcinoma amenable surgery radiotherapy . II . Evaluate response ( confirm unconfirmed partial response complete response ) rate regimen patient population . III . Assess nature degree toxicity regimen patient . OUTLINE : Patients receive paclitaxel IV 3 hour , amifostine IV 10 minute , follow fifteen minute later carboplatin IV 30-60 minute day 1 . Courses repeat every 28 day . Treatment continue 6 course absence disease progression . Patients follow every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 35 50 patient accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic , recurrent , refractory epithelial endometrial carcinoma Must one follow histologic type : Endometrioid adenocarcinoma Villoglandular Secretory Ciliated Endometrioid adenocarcinoma squamous differentiation Serous carcinoma Clear cell carcinoma Mucinous carcinoma Squamous carcinoma Mixed type carcinoma Undifferentiated carcinoma Must amenable surgery radiotherapy Documented evidence progression site site measurable disease irradiate Metastatic site need biopsied Measurable disease PATIENT CHARACTERISTICS : Age : 16 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT great 2 time ULN Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 25 mL/min Other : At least 5 year since prior malignancy except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy No 1 prior biologic therapy regimen Chemotherapy : No concurrent chemotherapy No prior taxane reason No 2 prior chemotherapy course use sole purpose radiosensitization primary definitive therapy allow No prior chemotherapy Endocrine therapy : No concurrent hormonal therapy Prior hormonal endocrine therapy allow Radiotherapy : No concurrent radiotherapy except site bone metastasis palliative control pain Prior radiotherapy 30 % bone marrow allow At least 4 week since radiotherapy recover Surgery : Prior surgery allow Must recover surgery complication therefrom</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>endometrial adenocarcinoma</keyword>
	<keyword>endometrial adenosquamous cell carcinoma</keyword>
	<keyword>endometrial clear cell carcinoma</keyword>
</DOC>